Emerging Growth Research Maintains Buy Rating for SBC Medical Group

Emerging Growth Research has reaffirmed its Buy-Extended rating on SBC Medical Group Holdings, Inc. (NASDAQ: SBC) following the company’s Q3:25 financial results. The firm has set a 12-month price target of $9.00, indicating substantial potential growth from SBC’s recent closing price of $3.57 on November 28, 2025. The report notes SBC’s revenue stabilization and operating profit improvements, reinforcing the company’s strategy for future growth.

Quarterly Performance Highlights

SBC Medical Group reported revenue of $43.4 million for Q3:25, which remained flat compared to the previous quarter but showed an 18% decline year-over-year due to adjustments in franchising fee structures. Management anticipates that the stabilization will persist through Q1:26 before the company resumes its historical growth trajectory.

Operating profit demonstrated a positive trend, rising to $15.9 million in Q3:25, up from $13.8 million in the same quarter last year and $14.6 million sequentially. This increase highlights the company’s effective cost management amid revenue pressures.

SBC also continued to expand its presence, adding 34 new clinic locations over the past year, bringing the total to 258 clinics. Customer visits grew to 6.5 million, with a commendable 72% repeat rate, reflecting a strong customer base. The average revenue per visit increased to $298, up from $275 earlier in the year.

Financial Stability and Future Growth Plans

The company concluded Q3:25 with a robust balance sheet, holding $127 million in cash and $83 million in accounts receivable, against just $21 million in long-term debt. This net cash position accounts for approximately 40% of SBC’s current market capitalization, providing a solid foundation for future initiatives.

Looking ahead, SBC’s management is optimistic about resuming revenue growth rates of 10% to 15% CAGR starting in 2026. This forecast is underpinned by a strategy to expand from 258 to 1,000 clinics over the next decade, along with plans for strategic mergers and acquisitions in Japan, Southeast Asia, and the United States.

SBC’s successful franchise model continues to yield high gross margins of 70% to 75%, positioning the company favorably in the competitive global cosmetic treatment market. Emerging Growth Research’s discounted cash flow analysis indicates a fair value of $8.88 per share, rounded to a target of $9.00. Sensitivity analyses suggest a potential range from $7.33 to $12.51 per share, depending on various growth and discount rate assumptions.

The company has also enhanced its liquidity through its inclusion in the Russell 3000 index, share buybacks, and is considering additional measures such as a potential dividend program and liquidity events for founder shares.

According to Emerging Growth Research, SBC Medical Group is currently navigating a challenging competitive landscape while adhering to operational discipline and laying the groundwork for long-term expansion.

For further details, the full Q3:25 quarterly update report can be accessed at Emerging Growth Research’s website.